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ABSTRACT 
Asthma is a complex disease and is no more considered as a single entity. It is an umbrella of term constituting 
many phenotypes, each varying in its clinical presentation and response to treatment1. Each phenotype 
requires specific approaches for control. But for an average clinician it is not practical to differentiate between 
phenotypes at least in the early stages of presentation. Hence all asthma patients pass through an ordeal of 
guideline based management. 
 
 
INTRODUCTION 
Asthma is a complex disease and is no more considered as a single entity. It is an umbrella of 
term constituting many phenotypes, each varying in its clinical presentation and response to 
treatment [1]. Each phenotype requires specific approaches for control. But for an average 
clinician it is not practical to differentiate between phenotypes at least in the early stages of 
presentation. Hence all asthma patients pass through an ordeal of guideline based 
management. It is reported that only 68% of patients get adequate control if treated under 
GINA guidelines. Hence more than 30% remains symptomatic and requires individualized 
management for control. If this subset of patients can be identified at the onset we can 
offer them early control and reduce morbidity. This also has a significant impact on cost of 
treatment. 
Specific treatments for asthma are unlikely to benefit all patients with asthma, but more 
likely target specific phenotypes. For example new approaches are needed for the 
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treatment of severe asthma, but patients need to be endotyped so that they can be directed 
for specific treatments. Severe asthma is a phenotype which includes three distinct types. 
They are the untreated severe asthma, difficult to treat severe asthma and therapy resistant 
asthma. So it is important that we recognize these entities as early as possible and subject 
them to individualized approach. Going further it is now understood that therapy resistant 
asthma comprises of two distinct entities such as patients who achieve good control but 
with maximum dose of the drug and those who are not controlled in spite of the maximum 
dose of drugs. Patients who do not respond to treatment remain a substantial part of the 
asthma burden. These patients again deserve separate strategy for management. More 
specifically, targeted novel treatments are needed in this group of patients. 
Focus on a specific target in a well defined phenotype of asthma is more likely to lead to a 
more successful treatment outcome than in a non phenotyped group. This can be 
accomplished by further grouping the phenotype based on pathophysiological 
characteristics. The addition of known pathophysiological mechanisms into the phenotypic 
characterization has been called endotyping [2]. 
Presence of eosinophils in sputum can be considered as a marker for targeted treatment. 
Sputum eosinophilia is defined as presence of 2% or more eosinophils in sputum samples. 
This is found in 36% of patients with asthma not treated with inhaled corticosteroid and in 
17% of patients taking inhaled Corticosteroids [3]. Measurement of sputum eosinophils 
could be used to guide asthma treatments [4], resulting in improved asthma control and 
fewer exacerbations. If sputum eosinophil count is less than 1% corticosteroid can be 
discontinued and if between 1-3% the existing steroid dose can be maintained and if it is 
more than 3%, that patient need to have higher dose of inhaled steroids or addition of oral 
steroids [5]. Patients with a subphenotype of severe asthma with recurrent exacerbations 
and sputum eosinophilia would benefit from anti-interleukin-5 treatments [6]. 
Another group is the neutrophil predominant endotype where the predominant cell type is 
neutrophils. Here the eosinophil count may be less than 1%.Neutrophilic asthma is 
predominant in patients with severe refractory asthma. Neutrophilic response might be 
indicative of a disease mechanism that is not driven by T-helper-2 cells and most likely, non-
steroid responsive asthma. Bacterial colonization in the airways of patients with severe 
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asthma and oral corticosteroid treatment can contribute to neutrophilic asthma. There is 
yet another group of patients with asthma who have mixed neutrophilia and eosinophilia in 
sputum and they have worse lung function, increased frequency of daily wheeze, and 
increased health-care utilization compared to other patients. Patients with poorly controlled 
asthma and a predominant sputum neutrophilia may benefit from antibacterial agents such 
as macrolides [7]. This is a readily identifiable group and comprises 10% of the difficult to 
treat asthma phenotype. 
Another subtype in the category of refractory asthma is those with airway hyper 
responsiveness (AHR). Measurements of AHR can be used as a tool to titrate anti-
inflammatory therapy. It is found that increasing the dose of corticosteroid in response to a 
reduction in methacholine PC20 appeared to improve asthma control. Bronchial 
thermoplasty is a novel mechanical therapy that has an effect on AHR. This treatment heats 
the proximal segmental airways in asthma through the application of a radiofrequency 
energy that breaks and damages the airway smooth muscle. Thermoplasty also reduced the 
amount of airway smooth muscle. With bronchial thermoplasty a 32% reduction was 
reported in the rate of severe exacerbations. 
MANAGEMENT 
On review of the above facts it is clear that the phenotype of severe asthma is not a single 
entity when pathophysiological features are considered. Hence the management of this 
entity needs different approach. Targeting the pathophysiological characteristic with new 
molecules or mechanical therapy can influence the control. For example, asthma 
exacerbations could be reduced by 40% using a highly targeted monoclonal antibody to IL-5 
(Mepolizumab)
6
 in patients with marked eosinophilic inflammation. Mepolizumab 
significantly reduced exacerbation rates [8], improved Asthma Quality of Life Questionnaire 
(AQLQ) scores,
 
and allowed oral prednisolone doses to be successfully reduced in refractory 
eosinophilic asthma. Other alternatives to oral corticosteroids in patients with a persistent 
sputum eosinophilia are methotrexate and oral cyclosporine. But both these drugs are 
known to produce potential life-threatening side-effects such as myelosuppression, and 
hepatotoxicity. 
Neutrophilic asthma is more common in smokers and obese females [9]. There is evidence 
that macrolides may specifically target neutrophilic airway inflammation. Mepolizumab 
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which is effectively used in eosinophilic inflammation do not have an impact on AHR. 
However AHR is used to titrate antiinflammatory therapy. It is found that stepping up 
corticosteroid therapy in response to a reduction in methacholine PC20 appeared to improve 
asthma control.  
Bronchial thermoplasty is a novel mechanical therapy that heats the proximal segmental 
airways in asthma through the application of a radiofrequency signal. Early clinical studies in 
mild-to-moderate asthma demonstrated an effect of bronchial thermoplasty upon AHR that 
persisted over 2 years. 
 
 
Endotype Characteristics Treatment 
Eosinophilic asthma Recurrent exacerbations; 
sputum eosinophils; Steroid-
dependent asthma 
Anti-interleukin-4 receptor 
α (Dupilumab), 
Anti-interleukin-5 
(Mepolizumab) 
Neutrophilic asthma Sputum neutrophils Macrolide antibiotics 
(Azithromycin) 
Asthma with airway 
hyperresponsiveness 
Poor control, Reduced 
Methacholine PC20 
Anti-interleukin-5 
(Mepolizumab), 
Bronchial Thermoplasty 
Table-1: Targeted therapy based on endotyping 
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CONCLUSION 
Severe asthma poses a significant health care burden accounting for up to 50% of the asthma 
budget. Managing patients with severe asthma is complex and requires a multidisciplinary approach 
and a standardized protocol. The difficult to treat group requires further typing based on 
pathophysiological characteristics in addition to their phenotypic variability. This should enable the 
physician to better target these characteristic and individualize the management. 
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